Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INT230-6 in early stage breast cancer
NCT04781725Phase 2Unknown
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Mar 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of INT230-6 in breast cancer, sponsored by Ottawa Hospital Research Institute. Status: unknown.
02
Drugs
INT230-6
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04781725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04781725.